N/A N=58 Basic Science

Obesity and Endogenous Oxalate Synthesis

Obesity

Bottom Line

View on ClinicalTrials.gov: NCT03808090 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2024

Primary outcome: Primary: Urinary Oxalate Excretion — 24 mg/day

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Normal Individuals (Dietary_supplement)
Age: Adult, Older Adult · 19+ yrs
Sex: All
Sponsor: University of Alabama at Birmingham
Primary completion: Jul 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Urinary Oxalate Excretion	24	—
SECONDARY Urinary Glycolate Excretion	32	—
SECONDARY Urinary Creatinine Excretion	1.47	—

Summary

The goal of this study is to determine if obesity is associated with increased endogenous oxalate synthesis as assessed by urinary oxalate excretion, which is a known risk factor for calcium oxalate kidney stones. The study will recruit adult participants without history of kidney stones. Participants will * Ingest fixed diets containing low amounts of oxalate for 4 days * Collect 24-hr urine samples during the fixed diet

Eligibility Criteria

Inclusion Criteria

Age 19-70 yrs Body Mass Index > 18.5 kg/m2 Normal fasting serum electrolytes on comprehensive metabolic profile Willing to ingest fixed diets

Exclusion Criteria

Chronic Kidney Disease, estimated glomerular filtration rate < 60 ml/mn/1.73m2 Primary hyperoxaluria Liver, endocrine or renal diseases or any other condition that may influence the absorption, transport or urinary excretion of ions, which will compromise the interpretation of results, including: Cystic fibrosis, Cystinuria, Uric acid stone former, Nephrotic syndrome, Sarcoidosis, Renal tubular acidosis, Primary hyperparathyroidism, Neurogenic bladder, Urinary diversion Pregnancy or breast-feeding Incompatible dietary requirements with the study, food allergies or intolerance to any of the foods in study menus Active malignancy or treatment for malignancy within 12 months prior to screening Utilization of immunosuppressive medication Uncontrolled Hypertension or diabetes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03808090). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.